CIRM Funded Clinical Trials

A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

Disease Area:
Brain Cancer
Investigator:
CIRM Grant:
CLIN2-13162 (Active)
Award Value:
$11,999,984.00
Trial Sponsor:
Beckman Research Institute of City of Hope
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A